Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy for Postmenopausal Estrogen Receptor-positive Breast Cancer: a Prospective Randomized Controlled Double-blind Phase IV Trial

With the development of neoadjuvant therapy for tumors, neoadjuvant chemotherapy (NAC) has become one of the most common and effective methods for preoperative systemic treatment of locally advanced breast cancer (LABC). Although epirubicin combined with cyclophosphamide and sequential docetaxel has been widely recognized as the first-line NAC for LABC, there are still some inoperable LABCs that are insensitive to chemotherapy and miss the opportunity of surgery, especially those with luminal A and low expression of Ki67. Therefore, neoadjuvant endocrine therapy has important clinical value for such patients. At present, the combination of aromatase inhibitor drugs and cyclin dependent kinase 4/6 can significantly improve the prognosis and survival of LABC compared with aromatase inhibitor monotherapy. However, whether inoperable LABC patients, especially those who are not susceptible to chemotherapy, can choose the combination of aromatase inhibitor drugs and cyclin dependent kinase 4/6 as neoadjuvant endocrine therapy to replace NAC remains unclear. Because the main principle of endocrine therapy is to induce tumor cell cycle arrest, leading to apoptosis of tumor cells, the effect is slower than that of chemotherapy. In addition, whether endocrine therapy can replace chemotherapy as a new adjuvant treatment for patients with inoperable LABC to improve the operability rate has not yet been fully evidenced. Therefore, this trial aims to conduct the prospective randomized controlled phase IV clinical trial of palbociclib combined with letrozole versus epirubicin combined with cyclophosphamide and sequential docetaxel as NAC to prove the efficacy of palbociclib combined with letrozole in postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression.

Study Overview

• Status: Not yet recruiting
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: palbociclib combined with letrozole; Drug: epirubicin combined with cyclophosphamide and sequential docetaxel

Detailed Description

reast cancer is one of the most prevalent malignant tumors in women, accounting for 23% of all malignant tumors. Approximately 1.3 million people are diagnosed with breast cancer every year in the world, and approximately 400,000 people die of breast cancer. The overall median survival time of patients with advanced breast cancer is only 2-3 years, and the 5-year survival rate is only about 20%. At present, a considerable number of patients are diagnosed as LABC at the time of initial diagnosis. Because of the wide range of lesions or poor lymph node status, surgical treatment is very difficult, and even some patients cannot be operated on.

With the development of neoadjuvant therapy for tumors, NAC has become one of the most common and effective methods for preoperative systemic treatment of LABC. The 2018 V2 version of the National Comprehensive Cancer Network guidelines for breast cancer diagnosis clearly states that preoperative chemotherapy for LABC should be based on an anthracyclines and can be combined with taxanes, but about 20% of LABC patients are not sensitive to this protocol. Heller et al. performed NAC with 5-fluorouracil + epirubicin + cyclophosphamide for 6 weeks in 88 patients with LABC, and the total effective rate was 78%. After 4 weeks of docetaxel treatment in patients with poor response, approximately 10% of patients are still not sensitive. In addition, many studies in and outside China have pointed out that the NAC effect in some estrogen receptor-positive LABC patients, especially postmenopausal luminal A patients, is worse than that of estrogen receptor negative or Ki67 overexpression patients. Ring et al. treated 435 cases of breast cancer with NAC of doxorubicin/cyclophosphamide or cyclophosphamide/methotrexate/fluorouracil. Pathological complete remission rate was 8.1% in estrogen receptor-positive patients and 21.6% in estrogen receptor negative patients. Similar results were obtained in NSABP B-27 test, with the ratio of 8.3% and 16.7% respectively. Simultaneously, Fashing et al. found that the pathological complete remission of patients with relatively high Ki67 after NAC with anthracyclines combined with taxanes was higher than that of patients with low Ki67. Many clinical studies in China have also obtained similar results; that is, the low expression of Ki67 indicates that the effect of NAC in LABC is not good.

Considering the above situation, some scholars gradually introduce endocrine therapy into the NAC of postmenopausal estrogen receptor-positive LABC, namely neoadjuvant endocrine therapy. At present, neoadjuvant endocrine therapy is practical and feasible for breast cancer with large tumors and positive hormone receptor. Simultaneously, the efficacy of the third-generation aromatase inhibitors is better than that of tamoxifen. Z1031 clinical trial of 381 patients with stage II or III postmenopausal estrogen receptor-positive breast cancer in the United States preliminarily confirmed that the third-generation aromatase inhibitors are currently the first choice of effective neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive breast cancer. However, 30% to 40% of breast cancer patients receiving endocrine therapy still have disease progression due to drug resistance, which is very disadvantageous for LABC patients. The emergence of cyclin dependent kinase 4/6 inhibitors has given hope to such patients. In the guidelines for advanced breast cancer, Cardoso et al. suggested that a first-line treatment with aromatase inhibitors combined with cyclin dependent kinase 4/6 inhibitors should be preferred. In a phase II randomized controlled trial to explore the treatment of estrogen receptor-positive and epidermal growth factor receptor-2-negative advanced breast cancer by combination of palbociclib, a cyclin dependent kinase 4/6 inhibitor, and letrozole, an aromatase inhibitor, the results found that the former could significantly prolong progression-free survival of hormone receptor-positive advanced breast cancer. Therefore, in February 2015, the US Food and Drug Administration approved the combination of palbociclib and letrozole for first-line treatment of hormone receptor-positive advanced breast cancer. However, for inoperable LABC patients, especially those who are not sensitive to chemotherapy, whether the combination of palbociclib and letrozole can be used as a neoadjuvant endocrine therapy instead of NAC is not clear. Although there are relatively few controlled studies on neoadjuvant endocrine therapy and NAC, the existing evidence suggests that the high level of Ki67 in hormone receptor-positive cases indicates that the effect of chemotherapy is better than that of endocrine therapy, but the adverse reaction rate of chemotherapy is high, especially for LABC or older and infirm patients, while neoadjuvant endocrine therapy can achieve similar effect to NAC. Therefore, the efficacy of palbociclib combined with letrozole as neoadjuvant endocrine therapy is still worth looking forward to. Because the principle of endocrine therapy is mainly to induce tumor cell cycle arrest, leading to apoptosis of cancer cells, so the effect is slower than that of chemotherapy. In addition, whether the efficacy can replace chemotherapy as NAC in inoperable LABC patients to improve the operability rate has not yet been fully evidenced.

Therefore, this trial aims to conduct the prospective randomized controlled phase IV clinical trial using palbociclib combined with letrozole versus epirubicin combined with cyclophosphamide and sequential docetaxel as NAC to prove the efficacy of palbociclib combined with letrozole in postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression.

• Study Type: Interventional
• Enrollment (Anticipated): 152
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Xi Gu, M.D.; Phone Number: +86 18940255116; Email: jadegx@163.com

Study Locations

• China
  • Liaoning
    • Shenyang, Liaoning, China, 110004
      • ShengJing Hospital Of China Medical University
      • Contact: Xi Gu; Phone Number: +86 18940255116; Email: jadegx@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 68 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• pathological examination confirms estrogen receptor positive, and Ki67 < 30% in breast cancer patients;
• postmenopausal women;
• tumor size stage ≥ T3, or lymph node stage ≥ N2, or ipsilateral upper extremity edema or the extent of lesions exceeds the scope of radical surgery;
• Karnofsky functional status score ≥ 70;
• normal findings of blood examination, normal liver and kidney functions, and basically normal electrocardiogram results before chemotherapy;
• age range from 18-70 years old.

Exclusion Criteria:

• history of anti-tumor treatment;
• inflammatory breast cancer or occult breast cancer;
• stage IV breast cancer;
• history of other malignant tumors;
• severe vital organ dysfunction, such as heart, liver and kidney or poor constitution cannot tolerate chemotherapy, or the treatment plan change due to intolerance during chemotherapy;
• cannot comply with the treatment because of mental and neurological diseases;
• dexamethasone contraindications or severe allergies to any drug in NAC;
• receiving NAC, but it is judged to be ineffective after two cycles of treatment, and other programs are forced to be used or chemotherapy is stopped to receive surgery;
• participation in other clinical trials.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: endocrine group; 76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into endocrine group.	Drug: palbociclib combined with letrozole; Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.; Other Names: Endocrine group
Other: chemotherapy group; 76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into chemotherapy group	Drug: epirubicin combined with cyclophosphamide and sequential docetaxel; Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.; Other Names: Chemotherapy group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical Response	Clinical response will be evaluated 5 years after treatment according to the regression of tumors. Tumor regression will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).	5 years after treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events	Any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment.	in 5 years
Breast-conserving rate	The percentage of patients receiving breast-conserving surgery 6 months after treatment	6 months after treatment
Operable rate	The percentage of patients who can undergo surgery 6 months after treatment	6 months after treatment
Ki67 expression in tumor tissues	Immunohistochemical staining will be used before treatment and 6 months and 5 years after treatment	Before treatment and 6 months and 5 years after treatment
Miller-Payne grading system	Assessment will be conducted before treatment, 6 months and 5 years after treatment. Grade 1: no reduction in the overall cellularity; grade 2: a minor loss of tumor cells but overall cellularity still high; up to 30% loss; grade 3: between an estimated 30% to 90% reduction in tumor cells; grade 4: more than 90% loss of tumor cells; grade 5: no malignant cells identifiable in sections from the site of tumor; however, ductal carcinoma in situ may be present.	Before treatment, 6 months and 5 years after treatment
Preoperative endocrine prognostic index	Assessment will be conducted 6 months and 5 years after treatment. Preoperative endocrine prognostic index is an independent predictor for breast cancer recurrence, based on tumor size, lymph node status, estrogen receptor status and Ki67 positive rate. The total score is 12. The higher the score, the worse the prognosis is.	6 months and 5 years after treatment
Progression-free survival	Progression-free survival refers to the time from random assignment in a clinical trial to disease progression or death from any cause	Within 5 years of follow-up
Overall survival	Overall survival refers to the time from group assignment to death	Within 5 years of follow-up

Collaborators and Investigators

• Sponsor: Shengjing Hospital
• Investigators: Principal Investigator: Caigang Liu, M.D., Ph.D., Shengjing Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): July 19, 2021
• Primary Completion (Anticipated): November 30, 2025
• Study Completion (Anticipated): May 31, 2026

Study Registration Dates

• First Submitted: October 22, 2019
• First Submitted That Met QC Criteria: October 22, 2019
• First Posted (Actual): October 24, 2019

Study Record Updates

• Last Update Posted (Actual): July 20, 2021
• Last Update Submitted That Met QC Criteria: July 18, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: adjuvant chemotherapy; letrozole; palbociclib; estrogen receptor
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Protein Kinase Inhibitors; Antibiotics, Antineoplastic; Hormone Antagonists; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Docetaxel; Cyclophosphamide; Epirubicin; Letrozole; Palbociclib
• Other Study ID Numbers: Shengjing-LCG003

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No